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ABSTRACT 
Background: Somatic point substitution mutations in the KRAS proto-oncogene primarily 
affect codons 12/13 where glycine is converted into other amino acids, and are highly prevalent 
in pancreatic, colorectal, and non-small cell lung cancers. These cohorts are non-responsive to 
anti-EGFR treatments, and are left with non-specific chemotherapy regimens as their sole 
treatment options. In the past, the development of peptide vaccines for cancer treatment was 
reported to have poor AT properties when inducing immune responses. Utilization of 
bioinformatics tools have since become an interesting approach in improving the design of 
peptide vaccines based on T- and B-cell epitope predictions. Methods: In this study, the region 
spanning exon 2 from the 4th to 18th codon within the peptide sequence of wtKRAS was 
chosen for sequence manipulation. Mutated G12V and G13D K-ras controls were generated in 
silico, along with additional single amino acid substitutions flanking the original codon 12/13 
mutations. IEDB was used for assessing human and mouse MHC class I/II epitope predictions, 
as well as linear B-cell epitopes predictions, while RNA secondary structure prediction was 
performed via CENTROIDFOLD. A scoring and ranking system was established in order to 
shortlist top mimotopes whereby normalized and reducing weighted scores were assigned to 
peptide sequences based on seven immunological parameters. Among the top 20 ranked 
peptide sequences, peptides of three mimotopes were synthesized and subjected to in vitro and 
in vivo immunoassays. Mice PBMCs were treated in vitro and subjected to cytokine assessment 
using CBA assay. Thereafter, mice were immunized and sera were subjected to IgG-based 
ELISA. Results: In silico immunogenicity prediction using IEDB tools shortlisted one G12V 
mimotope (68-V) and two G13D mimotopes (164-D, 224-D) from a total of 1,680 candidates. 
Shortlisted mimotopes were predicted to promote high MHC-II and -I affinities with optimized 
B-cell epitopes. CBA assay indicated that: 224-D induced secretions of IL-4, IL-5, IL-10, IL-
12p70, and IL-21; 164-D triggered IL-10 and TNF-α; while 68-V showed no immunological 
responses. Specific-IgG sera titers against mutated K-ras antigens from 164-D immunized 
Balb/c mice were also elevated post first and second boosters compared to wild-type and 
G12/G13 controls. Discussion: In silico-guided predictions of mutated K-ras T- and B-cell 
epitopes were successful in identifying two immunogens with high predictive scores, Th-bias 
cytokine induction and IgG-specific stimulation. Developments of such immunogens are 
potentially useful for future immunotherapeutic and diagnostic applications against KRAS(+) 
malignancies, monoclonal antibody production, and various other research and development 
initiatives. 
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